Each CME-accredited program can be used to gain a maximum of one (1.0) AMA PRA Category 1 CreditsTM through completion of a questionnaire concerning the program content.
The faculty have suggested some relevant references for listeners who would like to find out more about the topic:
Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37(6):393–401.
Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002;111(2):279–89.
Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 2007;12 March;[E-pub ahead of print].
Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111(1):97–109.
Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111(1):179–85.
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999;104(2):e20.
Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005;15(5):764–76.
The faculty have provided some slides to accompany program 2 of Talking ADHD.
Click here to start the slide show